Member Info for emptyend

Who?

Just because a bidder turns up at what might be perceived as an inopportune moment, it doesn’t mean a deal won’t be done. For the reasons you list, it would be perfect timing for a bidder…..

Every now and then I wonder whether a takeover bid is imminent.

Today is one of those times.

There is a lot going on, contractwise….

Visiting, Ruck. Big tour. That was a nice ride - better than I’d expected.

If you wish. I went on this a few weeks ago….

https://puffingbilly.com.au/

……plenty of twist and turns, pretty slow progress, occasional great views, seemed to go on quite a long time despite completely stopping occasionally……but got there in the end.

I see it more like a funicular railway, in which there are frequent hiatuses in an ascent, leaving passengers with the opportunity to get out, twiddle their thumbs and admire the view. Those who get off for such purposes need to remember to get back on again…..

I saw that in The Telegraph. It didn’t sound especially aggressive. Still, I would hope her consultant is aware of the SCOPE trials….

If you’ve ever seen the way Indian power and comms cables are installed, you’d appreciate that it isn’t an easy task to map them. I think all that the article is saying that the initial mapping was incomplete.

Ruck is correct. This RNS (whilst welcome and prompt) is not a dial-shifter. It merely confirms what we were told to expect in November really.

They’ve hired a professional sector-focused set of advisers - they know what they are doing and, when game-changing news turns up, I’m sure it won’t be undersold.

….talking of valuations…..

https://www.telegraph.co.uk/business/2024/01/18/wall-street-raiders-battling-control-smart-meters/

Nobody can control whether MHRA sign-offs happen on a good day or a bad day. News needs to be released promptly when it happens.

I’d settle for the next trial results being on a day when institutions or industry players are actively looking out for “the next big thing” - and breaking out above 30p on the back of it.

Re Burble’s lengthy list, I’m reminded of the Monty Python scene : “…but apart from that, what have the Romans ever done for us??”

😁

The word “exceptional” is important - because it completely explains why MHRA has been helpfully expediting approvals.

It may be worth remembering Chancellor Jeremy Hunt’s comment last year:

“ And with an extra £10m of funding over the next two years they (the MHRA) will put in place the quickest, simplest, regulatory approval in the world for companies seeking rapid market access.”

….because they clearly were advised of this this morning!!

Well at least this promptly validates the point in the November RNS:

“ Scancell has also received MHRA correspondence requesting a preclinical mouse safety study with iSCIB1+ prior to resubmission of the amendment to the current trial protocol to include a new parallel cohort with the double CPIs with iSCIB1+. Management do not see any potential issue with this regulatory request having previously completed identical studies with SCIB1. The iSCIB1+ cohort is now expected to start in Q1 2024.”

It does appear that the MHRA are indeed being responsive……which is both helpful and somewhat intriguing….

Https://www.lse.co.uk/rns/SCLP/update-on-scope-trial-xyrhx622822790d.html

Due imminently, I think. News re Vietnam will feature - but what?

Have a Chang for me tf…..👍

….not sure about the “should” but I do.

……if not sooner.

Re Stifel, maybe they have “the other half of the deal” in the form of an American client?

And if Scancell are now attracting sector specialists, why should there only be 4 or 5 with an interest?

This is complete nonsense:

lThe RNS regarding DJP's transfer of stock was not required, given no difference in material number of shares. It was released because they needed to silence thoughts here of what could have been going on, and probably still are.”

If the company are advised of a change of legal ownership of shares in which a director has an interest then the are obliged to tell the market of that. This isn’t the first time that such an RNS has been released by CC and it won’t be the last.